In the case of PRLR, only a few attempts have successfully developed a potential therapeutic small molecule inhibitor or monoclonal antibody (LFA102) to block PRLR signaling induced cell proliferation in breast cancer cell lines (101). Here, PRLR is linked to breast carcinoma.